CheckMan Stock Market Overview

Cooper-Standard Holdings Inc. (CPS) Presents at J.P. Morgan Automotive Conference Transcript

RingCentral, Inc. (RNG) Presents at Oppenheimer 29th Annual Technology, Internet & Communications Conference Transcript

DLR's growth outlook is strengthening on AI, cloud and enterprise demand, but rich valuation and a larger development program raise execution stakes.

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

Missile shortages and a Pentagon production push could boost Lockheed Martin, RTX and defense ETFs as replenishment drives new orders.

Intel Corp (NASDAQ:INTC, XETRA:INL) priced roughly $20 billion in new equity this week, a move analysts at BofA Securities said reflects growing confidence in the chipmaker's foundry business rather than a defensive balance-sheet play. The bank estimates the offering, which includes a 15% greenshoe option, will dilute earnings per share by about 4-5% on the higher share count.